Berberine Improves Insulin Sensitivity by Inhibiting Fat Store and Adjusting Adipokines Profile in Human Preadipocytes and Metabolic Syndrome Patients
Table 1
The general information and laboratory data of the new diagnosed metabolic syndrome patients at the baseline and 12 weeks after the therapy.
Before medication
After medication
value
Participants (M/F)
37 (17/20)
37 (17/20)
Age (years)
Body mass index (kg/m2)
<0.01
Waist circumference (cm)
0.04
Systolic pressure (mmHg)
0.32
Diastolic pressure (mmHg)
0.24
Total cholesterol (mM)
0.03
High-density lipoprotein cholesterol (mM)
0.06
Low-density lipoprotein cholesterol (mM)
0.03
Triglyceride (mM)
<0.01
Fasting plasma glucose (mM)
0.03
HbA1c (%)
0.02
Leptin (ug/L)
8.01 (2.04~15.17)
5.12 (1.88~12.89)
0.04
Adiponectin (mg/L)
8.42 (4.75~14.81)
10.02 (5.13~15.59)
0.14
Leptin/adiponectin
0.76 (0.29~2.85)
0.58 (0.14~1.22)
0.02
Fasting insulin (mIU/L)
16.90 (11.6~20.1)
12.50 (9.7~14.8)
0.04
HOMA-IR
5.46 (3.62~6.69)
3.25 (2.50~4.58)
0.03
Glutamic-pyruvic transaminase (U/L)
0.62
γ-Glutamyl transpeptidase (U/L)
0.74
Creatinine (mM)
0.77
t-test of paired measurement data comparisons between two comparing lines before and after medication. Data of nonnormal distribution were described using the median (M) and quartile (Q1~Q4).
